![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Recent initiatives in the public and private sector will bring forward completion of the human genome sequencing project. These developments have given greater emphasis to uncertainties over the implications of patents for expressed sequence tags (ESTs) and single nucleotide polymorphisms (SNPs). In the absence of firm guidance from public policy, inventors, particularly those from the private sector can be expected to file patent applications vigorously on partial and full DNA sequences. Unless the value of royalty payments for patents on partial DNA sequences is reasonably modest, the patent system risks failing the very innovation system it was established to promote.